Quipt Home Medical Corp. (NASDAQ:QIPT – Get Rating) – Equities research analysts at Raymond James increased their Q1 2023 earnings per share (EPS) estimates for shares of Quipt Home Medical in a research note issued on Wednesday, January 4th. Raymond James analyst R. Sarugaser now anticipates that the company will post earnings per share of $0.10 for the quarter, up from their previous estimate of $0.07. Raymond James currently has a “Outperform” rating and a $14.00 price objective on the stock. The consensus estimate for Quipt Home Medical’s current full-year earnings is $0.29 per share. Raymond James also issued estimates for Quipt Home Medical’s FY2023 earnings at $0.36 EPS, Q1 2024 earnings at $0.12 EPS, Q2 2024 earnings at $0.13 EPS, Q3 2024 earnings at $0.14 EPS, Q4 2024 earnings at $0.15 EPS, FY2024 earnings at $0.53 EPS, FY2025 earnings at $0.68 EPS and FY2026 earnings at $1.13 EPS.
Quipt Home Medical (NASDAQ:QIPT – Get Rating) last posted its quarterly earnings results on Wednesday, December 21st. The company reported $0.05 EPS for the quarter, beating the consensus estimate of $0.04 by $0.01. The business had revenue of $40.09 million during the quarter, compared to analysts’ expectations of $40.50 million. Quipt Home Medical had a return on equity of 7.13% and a net margin of 3.46%.
Separately, Canaccord Genuity Group raised their price target on Quipt Home Medical from C$11.00 to C$11.25 in a report on Monday, October 24th.
Quipt Home Medical Stock Up 12.3 %
QIPT opened at $5.37 on Thursday. The company has a debt-to-equity ratio of 0.14, a current ratio of 1.00 and a quick ratio of 0.62. The business has a 50 day simple moving average of $4.49 and a 200-day simple moving average of $4.68. The stock has a market capitalization of $191.17 million, a P/E ratio of 41.31 and a beta of 0.43. Quipt Home Medical has a 12 month low of $3.89 and a 12 month high of $6.00.
Hedge Funds Weigh In On Quipt Home Medical
Several hedge funds and other institutional investors have recently bought and sold shares of QIPT. Russell Investments Group Ltd. acquired a new position in Quipt Home Medical during the second quarter worth $1,744,000. First Manhattan Co. raised its holdings in Quipt Home Medical by 56.9% during the first quarter. First Manhattan Co. now owns 951,250 shares of the company’s stock worth $4,175,000 after purchasing an additional 345,000 shares during the last quarter. CLARET ASSET MANAGEMENT Corp raised its holdings in Quipt Home Medical by 2.1% during the second quarter. CLARET ASSET MANAGEMENT Corp now owns 2,906,343 shares of the company’s stock worth $13,296,000 after purchasing an additional 58,481 shares during the last quarter. Citadel Advisors LLC raised its holdings in Quipt Home Medical by 304.7% during the third quarter. Citadel Advisors LLC now owns 26,204 shares of the company’s stock worth $109,000 after purchasing an additional 39,004 shares during the last quarter. Finally, Diker Management LLC acquired a new position in Quipt Home Medical during the third quarter worth $129,000. 26.14% of the stock is owned by institutional investors and hedge funds.
Quipt Home Medical Company Profile
Quipt Home Medical Corp. provides in-home medical equipment and supplies, and respiratory and durable medical equipment in the United States. The company also offers management of various chronic disease states focusing on patients with heart and pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider Quipt Home Medical, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Quipt Home Medical wasn’t on the list.
While Quipt Home Medical currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
20 Stocks to Sell Now
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by entering your email address below.
Get This Free Report